Zynerba Pharmaceuticals Inc

NASDAQ:ZYNE  
4.50
+0.49 (+12.22%)
Regulatory, Other Pre-Announcement

Zynerba Pharmaceuticals Provides Regulatory Update On Zygel In Fragile X Syndrome

Published: 12/17/2020 11:40 GMT
Zynerba Pharmaceuticals Inc (ZYNE) - Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome.
Zynerba Pharmaceuticals - Plans to Conduct Placebo-controlled Pivotal Trial in Patients With Fxs Who Have Highly Methylated Fmr1 Gene.
Zynerba Pharmaceuticals Inc - Expects That Its Cash Runway Will Extend Into Beginning of 2023 As a Result of These Changes to Its Development Plans.
Zynerba Pharmaceuticals - in H1 2021, to Review Zygel Trial Design, Protocol for New Trial Through Type C Meeting With FDA.
Zynerba Pharmaceuticals - Expects to Initiate Zygel Pivotal Trial Before End of 2021.